Dong, Lei
Xiang, Jianxing
Babcock, Michael
Cheng, Yuanzhi
Wang, Yan
Shen, Yuqiao
Li, Li
Tan, Liping
Garovoy, Marvin
Hu, Wei
Zheng, Jianhong http://orcid.org/0009-0002-2423-324X
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral AL01211 in Healthy Chinese Volunteers
https://doi.org/10.1007/s40261-024-01362-2
Funding for this research was provided by:
AceLink Therapeutics, Inc.
Article History
Accepted: 16 April 2024
First Online: 2 May 2024
Declarations
:
: This study was funded by AceLink Therapeutics, Inc.
: J.X., M.B., Y.S., L.L., and J.Z. are full-time employees of AceLink Therapeutics. L.T. and M.G. were AceLink Therapeutics employees at the time of this study. L.D., Y.C., Y.W., and W.H. have no relevant financial or non-financial competing interests to report.
: This study was approved by the Ethics Committee of the Second Hospital of Anhui Medical University (approval number: YW2022-050(F1); approval date: 25 April 2022) and was conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation (ICH) guidelines for Good Clinical Practice (GCP).
: All volunteers gave their written informed consent prior to any study-related procedure.
: Not applicable.
: The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: M.B., J.Z., Y.S., M.G., and W.H. were responsible for study concept and study design. L.D., Y.C., Y.W., L.L., L.T., W.H., and J.Z. were responsible for study conduct and data acquisition. L.D., J.X., M.B., W.H., and J.Z. were responsible for analysis and interpretation. J.X. was responsible for original draft preparation. M.B., L.D., Y.S., M.G., J.Z., and W.H. were responsible for draft review and editing. All authors have read and agreed to the final version of this manuscript.